{
    "title": "Sanofi sees faster profit growth on Dupixent, flu vaccine demand",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11364533/Sanofi-sees-faster-profit-growth-Dupixent-flu-vaccine-demand.html",
    "date": "2022-10-28",
    "keywords": [
        "drug",
        "sanofi",
        "dupixent",
        "value",
        "cancer",
        "development",
        "growth",
        "analyst",
        "burger",
        "rise",
        "share",
        "income",
        "trial",
        "chatillon",
        "revenue",
        "consensus",
        "company",
        "vaccine",
        "launch",
        "highprice",
        "rate",
        "bln",
        "asset",
        "drugmaker",
        "forecast",
        "year",
        "demand",
        "flu",
        "price",
        "account",
        "currency",
        "impact",
        "thirdquarter",
        "business",
        "interest",
        "tax",
        "estimate",
        "august",
        "breast",
        "candidate",
        "heightening",
        "pipeline",
        "zantac",
        "credit",
        "suisse",
        "finance",
        "jeanbaptiste",
        "discount",
        "friday",
        "strategy",
        "call",
        "setback",
        "project",
        "synthorx",
        "market",
        "result",
        "exzema",
        "regeneron",
        "quarter",
        "half",
        "uptake",
        "highdose",
        "cfo",
        "production",
        "rampup",
        "distribution",
        "appetite",
        "population",
        "dollar",
        "group",
        "fenton",
        "david"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}